Lv3
400 积分 2026-01-28 加入
MA02.07 Efficacy and Safety of GFH375 in Advanced Non-small Cell Lung Cancer Patients with KRAS G12D Mutation
18天前
已完结
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
1个月前
已完结
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
1个月前
已完结
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
1个月前
已完结
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
1个月前
已完结
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
1个月前
已完结
Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management
2个月前
已完结
Teclistamab in Relapsed or Refractory Multiple Myeloma
2个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
2个月前
已完结
Remibrutinib in Chronic Spontaneous Urticaria
2个月前
已完结
皖公网安备34019202002308
